Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Starting antiretroviral therapy very early shrinks the latent viral reservoir and improves the prospects for attaining a functional cure.
A cross-sectional study asked 50 people which of six different models of care would make HIV treatment doable for them.
The first data from the much anticipated REPRIEVE trial on statin medications for people with HIV are out.
Lenacapavir, a twice-yearly injectable, suppresses viral load in people with highly resistant virus.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
These encouraging results do not apply, however, to people who remain undiagnosed.
A low-barrier HIV care program with access to multiple services in one place can help.
The Department of Health and Human Services recently updated its antiretroviral treatment and opportunistic infection guidelines.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
People who started treatment on the same day as their HIV diagnosis achieved an undetectable viral load sooner.
Maunank Shah, MD, PhD, is building a mobile version of HIV-ASSIST thanks to a Campbell Foundation grant.
This quick-reference chart compares antiretroviral (ARV) options for the treatment of HIV, including adult dosing and dietary restrictions.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
Taking antiretrovirals for four consecutive days each week followed by a three-day break may maintain suppression as well as daily pills.
Researchers address unanswered questions about HIV transmission through breastfeeding and injection drug use.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.